Thus, it is hypothesized that multi-targeted combination therapy using c-Met inhibitor could be appealing to enhance treatment effects of anti-HER2 targeted therapies and chemosensitize HER2-positive BC. The gene discussed is ERBB2; the disease is breast cancer.